



Nobel Prize awarded to mariPOC sister technology

The year 2014 Nobel Prize in Chemistry has been awarded to a Professor Stefan W. Hell for the development of super-resolved fluorescence microscopy. The technology shares a common background with the TPX technology which is employed in the mariPOC[®] diagnostic platform.

Professor Hell made the original technology innovation during 1993-1996 when he worked as a postdoctoral researcher at Professor Erkki Soini's Laboratory of Biophysics, University of Turku, Finland. Later on Professor Hell continued his research in imaging microscopy at Max-Planck Institute, Göttingen, Germany, while Professor Soini continued the development of the technology and its applications in the field of *in vitro* diagnostics. As a result of these research activities, the TPX technology (Two-Photon Excitation) was developed and later commercialized by Professor Soini's start-up company ArcDia International Ltd. In 2010, ArcDia launched the mariPOC[®] test system for rapid diagnostics of infectious diseases.

Many of ArcDia's current key-employees are co-workers of Professor Hell from the early times. "The Nobel Prize is clearly an acknowledgement to the biophysics research of Turku University", says Dr. Aleksi Soini, the CEO of ArcDia International Ltd. ArcDia's proprietary detection technology is based on the same optical phenomenon as the microscopy imaging now awarded with the Nobel Prize. ArcDia is the only company in the world to employ this unique technology in *in vitro* diagnostics. We believe the Nobel award will further increase the commercial attraction of the technology within the global health care industry", continues Dr. Soini.

About ArcDia

ArcDia International Ltd is the manufacturer of mariPOC®, the world's first multianalyte point-of-care diagnostics test for respiratory tract infections. In the future, the company will develop additional point-of-care tests based on its proprietary ArcDia™ TPX detection technology. Currently, ArcDia is actively seeking business partners for further market expansion. For more information, visit www.arcdia.com.

About mariPOC®

mariPOC® provides multianalyte diagnostic results for influenza-like illnesses and tonsillitis in near patient settings in 20 minutes. The mariPOC® applications are targeted for acute respiratory infections, the most common infectious disease on Earth. mariPOC® is superior in performance compared to the conventional test methods, including lateral flow rapid tests and standard bacterial culture. mariPOC® is designed to improve patient management and quality of health care, and it allows timely pathogen-specific diagnostics and medication.

